● Recruiting

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Condition: Colorectal Cancer · Peritoneal Metastases · Carcinomatosis · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1/Phase 2

Planned participants28

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.

This description comes directly from the study's public registry record.

Talk to the study team

Paula M Smith, MD · 713-792-3785 · psmith7@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07411599